Ralph Jiang
Overview
Explore the profile of Ralph Jiang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
84
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miller S, Jiang R, Schipper M, Fritsche L, Strohbehn G, Wallace B, et al.
Lancet Oncol
. 2024 Nov;
25(12):1666-1676.
PMID: 39551068
Background: Black patients were severely under-represented in the clinical trials that led to the approval of immune checkpoint inhibitors (ICIs) for all cancers. The aim of this study was to...
2.
Miller S, Schipper M, Fritsche L, Jiang R, Strohbehn G, Otles E, et al.
Cancer Med
. 2024 Nov;
13(21):e70379.
PMID: 39508134
Background: The cumulative, health system-wide survival benefit of immune checkpoint inhibitors (ICIs) is unclear, particularly among real-world patients with limited life expectancies and among subgroups poorly represented on clinical trials....
3.
Abusamra S, Solorzano M, Quarles J, Luke M, Patel M, Vince Jr R, et al.
Urol Pract
. 2024 Oct;
12(1):63-72.
PMID: 39383006
Introduction: There is increasing awareness that patients with prostate cancer frequently harbor germline variants that may carry important implications for them and their family members. Given the variable clinical guidelines,...
4.
Bryant A, Zamora-Resendiz R, Dai X, Morrow D, Lin Y, Jungles K, et al.
Cancer Med
. 2024 Jun;
13(12):e7253.
PMID: 38899720
Purpose: Real world evidence is crucial to understanding the diffusion of new oncologic therapies, monitoring cancer outcomes, and detecting unexpected toxicities. In practice, real world evidence is challenging to collect...
5.
Edwards D, Pirzadeh M, Van T, Jiang R, Tate A, Schaefer G, et al.
Cancer
. 2024 Jun;
130(17):2910-2917.
PMID: 38853532
Background: Despite randomized trials demonstrating a mortality benefit to low-dose computed tomography screening to detect lung cancer, uptake of lung cancer screening (LCS) has been slow, and the benefits of...
6.
Gharzai L, Jiang R, Jaworski E, Morales Rivera K, Dess R, Jackson W, et al.
NEJM Evid
. 2024 Feb;
2(4):EVIDoa2200195.
PMID: 38320030
BACKGROUND: The Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) working group identified metastasis-free survival as a valid surrogate end point for overall survival (OS) for patients with localized...
7.
Edwards D, Sankar K, Alseri A, Jiang R, Schipper M, Miller S, et al.
Int J Radiat Oncol Biol Phys
. 2023 Oct;
118(4):963-970.
PMID: 37793573
Purpose: Adjuvant durvalumab after definitive chemoradiotherapy (CRT) for unresectable stage III non-small cell lung cancer (NSCLC) is well-tolerated in clinical trials. However, pneumonitis rates outside of clinical trials remain poorly...
8.
Vince Jr R, Jiang R, Bank M, Quarles J, Patel M, Sun Y, et al.
JAMA Netw Open
. 2023 Jan;
6(1):e2250416.
PMID: 36630135
Importance: As the field of medicine strives for equity in care, research showing the association of social determinants of health (SDOH) with poorer health care outcomes is needed to better...
9.
Hammer L, Jiang R, Hearn J, Lashbrook J, Mitchell A, Daignault-Newton S, et al.
Int J Radiat Oncol Biol Phys
. 2022 Jul;
115(1):132-141.
PMID: 35878714
Purpose: Men with locally advanced prostate cancer who undergo radical prostatectomy (RP) often develop recurrence and require postoperative radiotherapy. We aimed to determine the safety of neoadjuvant stereotactic body radiotherapy...
10.
Hinton T, Karnak D, Tang M, Jiang R, Luo Y, Boonstra P, et al.
Transl Oncol
. 2022 Apr;
21:101428.
PMID: 35460942
Grade 2 and higher radiation pneumonitis (RP2) is a potentially fatal toxicity that limits efficacy of radiation therapy (RT). We wished to identify a combined biomarker signature of circulating miRNAs...